JP2020022459A5 - - Google Patents

Download PDF

Info

Publication number
JP2020022459A5
JP2020022459A5 JP2019169775A JP2019169775A JP2020022459A5 JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5 JP 2019169775 A JP2019169775 A JP 2019169775A JP 2019169775 A JP2019169775 A JP 2019169775A JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5
Authority
JP
Japan
Prior art keywords
seq
adenovirus
vector
transgene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019169775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020022459A (ja
JP7394285B2 (ja
Filing date
Publication date
Priority claimed from JP2018137237A external-priority patent/JP6970647B2/ja
Application filed filed Critical
Publication of JP2020022459A publication Critical patent/JP2020022459A/ja
Publication of JP2020022459A5 publication Critical patent/JP2020022459A5/ja
Application granted granted Critical
Publication of JP7394285B2 publication Critical patent/JP7394285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019169775A 2011-10-05 2019-09-18 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法 Active JP7394285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543661P 2011-10-05 2011-10-05
US61/543,661 2011-10-05
JP2018137237A JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018137237A Division JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Publications (3)

Publication Number Publication Date
JP2020022459A JP2020022459A (ja) 2020-02-13
JP2020022459A5 true JP2020022459A5 (cg-RX-API-DMAC7.html) 2020-03-26
JP7394285B2 JP7394285B2 (ja) 2023-12-08

Family

ID=47045181

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2019169775A Active JP7394285B2 (ja) 2011-10-05 2019-09-18 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Country Status (7)

Country Link
US (4) US9617560B2 (cg-RX-API-DMAC7.html)
EP (1) EP2764014B1 (cg-RX-API-DMAC7.html)
JP (3) JP6757121B2 (cg-RX-API-DMAC7.html)
CN (2) CN107574154A (cg-RX-API-DMAC7.html)
BR (1) BR112014008284A2 (cg-RX-API-DMAC7.html)
CA (1) CA2851251C (cg-RX-API-DMAC7.html)
WO (1) WO2013052832A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764014B1 (en) 2011-10-05 2022-02-09 GenVec, Inc. Adenoviral vectors and methods of use
CN107937440A (zh) * 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
IN2014DN03005A (cg-RX-API-DMAC7.html) 2011-10-05 2015-05-08 Genvec Inc
US9676824B2 (en) * 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
JP7118062B2 (ja) 2016-12-09 2022-08-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リサウイルス抗原を有するチンパンジーアデノウイルス構築物
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
US11142551B2 (en) * 2017-10-31 2021-10-12 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
AU2019231652B2 (en) 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2021072129A2 (en) 2019-10-08 2021-04-15 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CZ287157B6 (en) 1993-07-13 2000-10-11 Rhone Poulenc Rorer Sa Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP0885012A4 (en) 1996-01-29 2001-09-05 Univ Georgetown MALARIA Vaccine, which also contains an MSA1 peptide
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
WO2003020879A2 (en) 2001-07-23 2003-03-13 Genvec, Inc. Cells and methods for propagating adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
CA2590943C (en) 2004-12-13 2013-10-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
DE102005006388A1 (de) * 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
RU2604815C2 (ru) 2009-02-02 2016-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Нуклеинокислотные и аминокислотные последовательности аденовируса обезьян, векторы, содержащие указанные последовательности, и их применение
EP2459716B1 (en) 2009-07-31 2016-08-17 Paxvax, Inc. Adenoviral-based vectors
JP5980117B2 (ja) 2009-11-09 2016-08-31 ジェンヴェック,インコーポレーテッド サルアデノウイルスベクターの増殖方法
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
EP2764014B1 (en) * 2011-10-05 2022-02-09 GenVec, Inc. Adenoviral vectors and methods of use
IN2014DN03005A (cg-RX-API-DMAC7.html) 2011-10-05 2015-05-08 Genvec Inc
CN107937440A (zh) * 2011-10-05 2018-04-20 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
EP2809346A1 (en) 2012-02-02 2014-12-10 GenVec, Inc. Adenoviral vector-based malaria vaccine
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine

Similar Documents

Publication Publication Date Title
JP2020022459A5 (cg-RX-API-DMAC7.html)
JP2018520997A5 (cg-RX-API-DMAC7.html)
JP2015096070A5 (cg-RX-API-DMAC7.html)
JP2023082054A5 (cg-RX-API-DMAC7.html)
JP2010227108A5 (cg-RX-API-DMAC7.html)
JP2021112211A5 (cg-RX-API-DMAC7.html)
JP2019214579A5 (cg-RX-API-DMAC7.html)
JP2010065037A5 (cg-RX-API-DMAC7.html)
JP2020505025A5 (cg-RX-API-DMAC7.html)
JP2016537341A5 (cg-RX-API-DMAC7.html)
JP2019522461A5 (cg-RX-API-DMAC7.html)
JP2012505657A5 (cg-RX-API-DMAC7.html)
JP2016146837A5 (cg-RX-API-DMAC7.html)
JP2011087580A5 (cg-RX-API-DMAC7.html)
JP2003514526A5 (cg-RX-API-DMAC7.html)
JP2017534262A5 (cg-RX-API-DMAC7.html)
JP2013539454A5 (cg-RX-API-DMAC7.html)
JP2017532302A5 (cg-RX-API-DMAC7.html)
JP2008525033A5 (cg-RX-API-DMAC7.html)
RU2019144161A (ru) Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
RU2015135890A (ru) Композиция вакцины
WO2017194903A3 (fr) Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune
RU2022105597A (ru) Искусственно созданная система управления функцией шк
JP2009523007A5 (cg-RX-API-DMAC7.html)
JP2010265269A5 (cg-RX-API-DMAC7.html)